Sanofi May Increase Sales Force Despite Need To Meet Post-Merger Savings Goal
This article was originally published in The Pink Sheet Daily
Executive Summary
The company says it is on target to achieve its previously announced $2.1 bil. in synergies and is not planning to cut its R&D and promotional budgets to achieve that number. Sanofi-Aventis says Acomplia pre-launch expenses will run into the hundreds of millions of euros.
You may also be interested in...
GSK Will Cut Sales Force And Reinvest In R&D If Pfizer Acts First
Company would “welcome” a decision by Pfizer to cut back its sales force, CEO Garnier declares. Analyst reports have ignited market speculation that Pfizer is ready to retool its sales and marketing infrastructure.
Acomplia Pricing Likely To Follow Statin Model, Sanofi Says
Sanofi is considering a range of pricing options for the weight-loss/smoking cessation agent, company says; price will ultimately depend on labeling. Statin model would be appropriate if Sanofi can position the drug as long-term therapy to reduce adverse health outcomes.
Sanofi-Aventis Merger Set; $65 Bil. Deal Means More Leverage With Managed Care
Sanofi-Aventis' $30 bil. pharma/vaccine business will provide bulk necessary to better negotiate discounts. Sanofi has not had much opportunity to work within U.S. managed care system, but says it will learn from Aventis.